Special Issue

Molecular Research on Urology

Guest Editors:

Prof. Dr. Jack A. Schalken
Research Director Urology,
Dept. of Urology, University
Hospital Nijmegen, Box 9101,
Nijmegen NL-6500 HB, The
Netherlands
jack.schalken@radboudumc.nl

Prof. Dr. Natasha Kyprianou
James F. Hardymon Chair in
Urology Research, Professor of
Urology, Biochemistry,
Pathology and Toxicology &
Cancer Biology University of
Kentucky College of Medicine,
Lexington, KY, United States,
United States
nkypr2@uky.edu

Deadline for manuscript
submissions:
30 June 2017

Message from the Guest Editors

Dear Colleagues,

Molecular technology platforms have exponentially developed to a status
where individual patient-acquired pathologies can be profiled at various
levels. Where does the technology meet unmet clinical needs?

In this Special Issue, we invite you to submit manuscripts that illustrate the
clinical utility and impact of molecular research into clinical urological
practice. We invite both oncological, as well as non-oncological papers.
Topics to be considered include, but are not limited to, precision medicine in
GU oncology, new molecular therapeutical targets, biomarkers for non-
oncological bladder disease, and advances in molecular tissue engineering.

Prof. Dr. Jack A. Schalken
Prof Dr. Natasha Kyprianou
Guest Editors

Author Benefits

| Open Access: | free for readers, with publishing fees paid by authors or their
institutions. |
| High visibility: | indexed by the Science Citation Index Expanded (Web of
Science), MEDLINE (PubMed) and other databases. |
| Rapid publication: | manuscripts are peer-reviewed and a first decision
provided to authors approximately 22 days after submission; acceptance to
publication is undertaken in 8 days (median values for 2016). |